Reviva Pharmaceuticals Hldg Inc (RVPH)

$0.50 -0.04 (-7.19%)
Market Cap 34.82M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,829,100
Avg Vol 11,777,500
Day's Range N/A - N/A
Shares Out 69.34M
Stochastic %K 35%
Beta -0.03
Analysts Strong Sell
Price Target $5.38

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408-501-8881
Fax: 408-904-6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
jgo1
jgo1 Nov. 16 at 2:29 PM
$RVPH Tomorrow will be the 5th business day since they received the delisting determination letter from Nasdaq according to the 10Q page 19. They noted rule 5810b that they must file 8K and PR this information within 5 business days, but will they just hide it in the 10Q and consider it done since they acknowledged the rule and it's in the 10Q from Thursday? Or will they be transparent and PR this tomorrow and illustrate a plan of action as required if they are facing a delisting determination panel?
1 · Reply
redwineswede
redwineswede Nov. 16 at 1:21 PM
$RVPH any new data in the poster released yesterday?
1 · Reply
Dubbyy
Dubbyy Nov. 16 at 6:39 AM
$RVPH Check out this article from TipRanks | Reviva Pharmaceuticals: Promising Future with Strong Financial Position and Positive Regulatory Outlook | https://tipranks.onelink.me/WJho/ptu73vkp
1 · Reply
KingKongBundee
KingKongBundee Nov. 16 at 5:22 AM
$RVPH RVPH’s drug directly threatens: • Vraylar ($8–9B peak) • Rexulti ($2–3B+) • Caplyta ($1.5–2.5B+) • Latuda ($3–4B historical) • Invega LAIs ($4–5B+) Every one of these franchises is owned by a company that has major strategic reasons to defend their position. When a next-gen product threatens: $20–30B of global annual revenue across incumbents …big pharma doesn’t ignore it. This is a textbook environment for competitive bidding.
0 · Reply
Anomalies
Anomalies Nov. 16 at 3:19 AM
$RVPH
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 7:43 PM
$RVPH
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 7:42 PM
$RVPH you would think Les would have some connections to bring some investors in- right?? He has been here 5 years now and on multiple boards...
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 6:04 PM
$RVPH he is a liar and would not hinge on any wording that he implies
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 6:02 PM
$RVPH could not agree more, every year they change auditors and fail to comply on time and to boot uncle fester doesn’t even buy shares- how is that King Kong???
1 · Reply
jgo1
jgo1 Nov. 15 at 3:01 PM
$RVPH How is it that RVPH hasn't at least made a CFO change over the years, mistake after mistake. All they needed to get the 180 day extension was stockholders equity to be over 5 million, it was 4.5 million. Why not get another million or more after the last offering instead of now having to face a delisting panel. Why not understand the Nasdaq requirements. Other mistakes, no offerings to raise cash when shares went to 9, and hovered over 4 for close to a year and dilution immediately after phase 3. Then 2 years in a row of material weakness when reporting 10K, first time crushing the stock price and lawsuit PR's came out. Last years price run in December and to only do offering for only 18 million dollars at dollar discount from market price. Than offer over 40 million shares for pennies. They're numerous other examples.
1 · Reply
Latest News on RVPH
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 4:05 PM EST - 3 days ago

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 28, 2025, 8:00 AM EDT - 19 days ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Oct 7, 2025, 4:08 PM EDT - 5 weeks ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 2 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 18, 2025, 9:26 PM EDT - 2 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Sep 18, 2025, 4:05 PM EDT - 2 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:25 PM EDT - 3 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025, 8:40 AM EDT - 5 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 4:05 PM EDT - 6 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025, 11:30 AM EDT - 8 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 10 months ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 10 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:00 AM EST - 11 months ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 11 months ago

Reviva Announces Proposed Public Offering

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11, 2024, 3:37 PM EST - 1 year ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Feb 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 25, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 20, 2023, 4:05 PM EST - 2 years ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 2 years ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 4:01 PM EST - 2 years ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Nov 2, 2023, 3:11 AM EDT - 2 years ago

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

jgo1
jgo1 Nov. 16 at 2:29 PM
$RVPH Tomorrow will be the 5th business day since they received the delisting determination letter from Nasdaq according to the 10Q page 19. They noted rule 5810b that they must file 8K and PR this information within 5 business days, but will they just hide it in the 10Q and consider it done since they acknowledged the rule and it's in the 10Q from Thursday? Or will they be transparent and PR this tomorrow and illustrate a plan of action as required if they are facing a delisting determination panel?
1 · Reply
redwineswede
redwineswede Nov. 16 at 1:21 PM
$RVPH any new data in the poster released yesterday?
1 · Reply
Dubbyy
Dubbyy Nov. 16 at 6:39 AM
$RVPH Check out this article from TipRanks | Reviva Pharmaceuticals: Promising Future with Strong Financial Position and Positive Regulatory Outlook | https://tipranks.onelink.me/WJho/ptu73vkp
1 · Reply
KingKongBundee
KingKongBundee Nov. 16 at 5:22 AM
$RVPH RVPH’s drug directly threatens: • Vraylar ($8–9B peak) • Rexulti ($2–3B+) • Caplyta ($1.5–2.5B+) • Latuda ($3–4B historical) • Invega LAIs ($4–5B+) Every one of these franchises is owned by a company that has major strategic reasons to defend their position. When a next-gen product threatens: $20–30B of global annual revenue across incumbents …big pharma doesn’t ignore it. This is a textbook environment for competitive bidding.
0 · Reply
Anomalies
Anomalies Nov. 16 at 3:19 AM
$RVPH
2 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 7:43 PM
$RVPH
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 7:42 PM
$RVPH you would think Les would have some connections to bring some investors in- right?? He has been here 5 years now and on multiple boards...
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 6:04 PM
$RVPH he is a liar and would not hinge on any wording that he implies
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Nov. 15 at 6:02 PM
$RVPH could not agree more, every year they change auditors and fail to comply on time and to boot uncle fester doesn’t even buy shares- how is that King Kong???
1 · Reply
jgo1
jgo1 Nov. 15 at 3:01 PM
$RVPH How is it that RVPH hasn't at least made a CFO change over the years, mistake after mistake. All they needed to get the 180 day extension was stockholders equity to be over 5 million, it was 4.5 million. Why not get another million or more after the last offering instead of now having to face a delisting panel. Why not understand the Nasdaq requirements. Other mistakes, no offerings to raise cash when shares went to 9, and hovered over 4 for close to a year and dilution immediately after phase 3. Then 2 years in a row of material weakness when reporting 10K, first time crushing the stock price and lawsuit PR's came out. Last years price run in December and to only do offering for only 18 million dollars at dollar discount from market price. Than offer over 40 million shares for pennies. They're numerous other examples.
1 · Reply
Stocks2Retire
Stocks2Retire Nov. 14 at 11:03 PM
$RVPH grok’s take on rvph.. recent updates.. Conclusion RVPH’s prospects have brightened with Q3 efficiencies, regulatory acceleration, and expanded IP, solidifying brilaroxazine’s path to NDA in Q2 2026. Forums echo this optimism but stress execution risks, aligning with a speculative buy for catalyst-driven upside. While financials remain tight, positive pre-NDA feedback could catalyze a multi-fold rally, though dilution and market inertia loom.
0 · Reply
Beardedchowder
Beardedchowder Nov. 14 at 10:36 PM
$RVPH yeah like a week ago, and a week before that and it was at .60 a month ago
1 · Reply
channelsurfer
channelsurfer Nov. 14 at 9:43 PM
$RVPH sorry to recycle my own post yet it’s pretty straightforward if you have more than a 5 second attention span (thanks tik tok / social media) and if can actually read (thanks dept of education).
0 · Reply
Weng_Weng
Weng_Weng Nov. 14 at 8:33 PM
$RVPH one day this will hit 55 cents
1 · Reply
DELLY2TIMES
DELLY2TIMES Nov. 14 at 6:52 PM
$RVPH any word on the extension here?? 4 days past the date
1 · Reply
DELLY2TIMES
DELLY2TIMES Nov. 14 at 6:48 PM
If you back out to the monthly, this thing has been coiling lower highs, higher lows, compressing, looks like the trend will have to break by Nov 27-28, needs a bounce off resistance at .466 if it gets that low. Not financial advice, I have a position in this and have been watching closely. Not financial advice do your own research, just food for thought $RVPH
0 · Reply
Shannon667
Shannon667 Nov. 14 at 6:35 PM
$RVPH
0 · Reply
PatriotTrader17
PatriotTrader17 Nov. 14 at 6:30 PM
$RVPH Big Mike in the house!!!!
0 · Reply
MTN52C
MTN52C Nov. 14 at 6:10 PM
$RVPH LOL
1 · Reply
hawkeye45691
hawkeye45691 Nov. 14 at 5:29 PM
$RVPH I am bullish on the stock but do think FDA will want the second study before filing the NDA.
2 · Reply
KingKongBundee
KingKongBundee Nov. 14 at 5:11 PM
$RVPH Did anyone else note how Reviva referred to the upcoming FDA meeting? They didn't just say "Type-B meeting." They specifically said "Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval..." That wording matters. A Pre-NDA is a Type-B meeting, but FDA does not schedule a Pre-NDA meeting unless: *The pivotal efficacy trial(s) are complete *Long-term safety requirements are met *CMC manufacturing plans are far enough along *The sponsor has a substantially complete data package You don't get a Pre-NDA meeting to talk about the program. You get one to talk about NDA submission logistics For CNS drugs especially, reaching the Pre-NDA stage is often one of the strongest signs that: *FDA engagement has been positive *There is no indication that additional trials are required *No major deficiencies have been raised *The regulatory path is moving from scientific to procedural Sometimes language shift is the only early tell you get. No guarantees, but the regulatory signals look +.
2 · Reply
alteralgo
alteralgo Nov. 14 at 4:17 PM
$RVPH You realise FDA approval is completely unrelated to listing requirements…
1 · Reply